All In Biotech

Drug Trial Radar · NCT02344654

Fluorescence Cholangiography During Cholecystectomy - a RCT

Fluorescence Cholangiography Versus X-ray Cholangiography During Laparoscopic Cholecystectomy for Complicated Gallstone Disease

Last checked: Nov 19, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

May 1, 2015

Primary completion

Aug 27, 2018

Study completion Aug 27, 2018

Sponsor

Lead sponsor
Hvidovre University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 26, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to compare the success rates of intraoperative fluorescent cholangiography using indocyanine green versus conventional X-ray cholangiography for the identification of bile duct anatomy during laparoscopic cholecystectomy for complicated gallstone disease in a randomized design with 120 patients.

Conditions

  • Cholecystitis
  • Gallstones

Interventions

  • Indocyanine greenDrug

  • Near-infrared illuminationDevice

    To see the fluorescence from indocyanine green

  • UrografinDrug

  • X-rayRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visualization of the cystic duct - common hepatic duct - common bile duct junctionTime frame: Intraoperative

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.